Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | OXTR | P30559 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082472 | 0.80 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL3100293 | 0.79 | FPR2 (0.63) | MEN1NPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL825281 | 0.77 | AVPR1A (0.56) | AVPR1AMEN1NPC1RAB9AKMT2A | |
| SCHEMBL825204 | 0.77 | AVPR1A (0.71) | AVPR1AOXTR | |
| SCHEMBL614997 | 0.77 | AVPR1A (1.00) | AVPR1AOXTRHTT | |
| SCHEMBL825151 | 0.76 | AVPR1A (0.56) | AVPR1AMEN1NPC1RAB9AKMT2A | |
| SCHEMBL615021 | 0.76 | AVPR1A (0.71) | AVPR1AOXTR | |
| SCHEMBL825326 | 0.76 | MEN1 (0.47) | AVPR1AMEN1NPC1RAB9AKMT2A | |
| SCHEMBL825328 | 0.76 | MEN1 (0.47) | AVPR1AMEN1NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL828376 | 0.75 | MEN1 (0.47) | AVPR1AMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143281-B2 | Indoles | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2125785-B1 | INDOLE-3-YL-CARBONYL-PIPERIDINE- DERIVATIVES FOR THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS VIA V1A RECEPTOR ANTAGONISM | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011132443-A1 | SURFACE ACOUSTIC WAVE DEVICE AND MANUFACTURING METHOD OF SAME | 株式会社村田製作所 (JP) | 2011-10-27 | — | — | WO | disclosed |
| EP-2125785-A1 | INDOLES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008080842-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167344-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167344-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167344-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161315-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161316-A1 | INDOLES | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161315-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885MEN1 2419/4885NPC1 4152/4885 |
| US-20080167344-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885MEN1 2419/4885NPC1 4152/4885 |
| US-20080161316-A1 | INDOLES | AVPR1A, HTR1A, AVPR1B | AVPR1A 1/4885MEN1 2419/4885NPC1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.